KR100512671B1 - 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물 - Google Patents

항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100512671B1
KR100512671B1 KR10-1999-7004656A KR19997004656A KR100512671B1 KR 100512671 B1 KR100512671 B1 KR 100512671B1 KR 19997004656 A KR19997004656 A KR 19997004656A KR 100512671 B1 KR100512671 B1 KR 100512671B1
Authority
KR
South Korea
Prior art keywords
platelet aggregation
compound
pharmaceutical composition
aggregation antagonist
antagonist compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7004656A
Other languages
English (en)
Korean (ko)
Other versions
KR20000057265A (ko
Inventor
우장앙드레
쿠라우듀알랑에이치
리들리로버트제이
둔위디에크리스토퍼티
페론마크에이치
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21861879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100512671(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20000057265A publication Critical patent/KR20000057265A/ko
Application granted granted Critical
Publication of KR100512671B1 publication Critical patent/KR100512671B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-1999-7004656A 1996-11-27 1997-11-24 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물 Expired - Fee Related KR100512671B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3187896P 1996-11-27 1996-11-27
US60/031,878 1996-11-27

Publications (2)

Publication Number Publication Date
KR20000057265A KR20000057265A (ko) 2000-09-15
KR100512671B1 true KR100512671B1 (ko) 2005-09-07

Family

ID=21861879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7004656A Expired - Fee Related KR100512671B1 (ko) 1996-11-27 1997-11-24 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물

Country Status (27)

Country Link
US (2) US6103705A (enExample)
EP (1) EP0946185B2 (enExample)
JP (1) JP4498471B2 (enExample)
KR (1) KR100512671B1 (enExample)
CN (1) CN1121224C (enExample)
AP (1) AP1390A (enExample)
AT (1) ATE283062T1 (enExample)
AU (1) AU754936B2 (enExample)
BG (1) BG64542B1 (enExample)
BR (1) BR9713141A (enExample)
CA (1) CA2272317C (enExample)
CZ (1) CZ298552B6 (enExample)
DE (1) DE69731763T3 (enExample)
DK (1) DK0946185T4 (enExample)
EA (1) EA002475B1 (enExample)
ES (1) ES2230624T5 (enExample)
HU (1) HUP9903496A3 (enExample)
IL (1) IL129877A (enExample)
NO (1) NO327740B1 (enExample)
OA (1) OA11049A (enExample)
PL (1) PL189116B1 (enExample)
PT (1) PT946185E (enExample)
SI (1) SI0946185T2 (enExample)
SK (1) SK286024B6 (enExample)
UA (1) UA63929C2 (enExample)
WO (1) WO1998023279A1 (enExample)
ZA (1) ZA9710691B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA63929C2 (uk) * 1996-11-27 2004-02-16 Aventis Pharm Prod Inc Фармацевтична композиція та продукт, що містить сполуки з анти-ха активністю і антагоніст агрегації тромбоцитів, спосіб і набір для лікування або профілактики захворювань, які супроводжують тромбоутворення
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
AU1712700A (en) * 1998-11-18 2000-06-05 G.D. Searle & Co. Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
PL353335A1 (en) * 1999-06-30 2003-11-17 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
KR20030069990A (ko) * 2000-09-08 2003-08-27 해밀톤 시빅 호스피탈즈 리서치 디벨로프먼트 인코포레이티드 항혈전 조성물
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ES2274013T3 (es) 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
CA2434430A1 (en) 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20040171819A1 (en) * 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR100601429B1 (ko) * 2004-07-09 2006-07-14 주식회사 대우일렉트로닉스 기계식 전자렌지의 댐퍼 구동회로
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
CN101783857B (zh) * 2009-05-12 2011-11-30 上海海事大学 一种基于fpga在高分辨率成像系统中的图像矩阵化预处理方法
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
RU2554803C1 (ru) * 2014-06-26 2015-06-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики развития послеоперационных венозных тромбоэмболических осложнений у пациентов с колоректальным раком

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022910A1 (en) * 1993-03-29 1994-10-13 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
WO1995010295A1 (en) * 1993-10-15 1995-04-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766167A (en) * 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
SE449753B (sv) * 1978-11-06 1987-05-18 Choay Sa Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
EP0066908B1 (en) * 1981-05-21 1985-08-28 Akzo N.V. New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4833155A (en) * 1986-11-25 1989-05-23 Syntex (U.S.A.) Inc. 3-(ω-(3,5,-di-t-butyl-4-hydroxyphenyl)-alkanoyl)pyrroles, and anti-inflammatory uses thereof
ES2052595T3 (es) * 1986-12-15 1994-07-16 Inst Nat Sante Rech Med Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1991004746A1 (en) * 1989-09-29 1991-04-18 Rhone-Poulenc Rorer International (Holdings) Inc. Anti-thrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
EP0522140A4 (en) * 1991-01-24 1993-03-03 Aerojet-General Corporation Electrochemical desensitization process
ATE217796T1 (de) * 1991-05-02 2002-06-15 Yeda Res & Dev Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO1997035592A1 (en) * 1996-03-28 1997-10-02 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
UA63929C2 (uk) * 1996-11-27 2004-02-16 Aventis Pharm Prod Inc Фармацевтична композиція та продукт, що містить сполуки з анти-ха активністю і антагоніст агрегації тромбоцитів, спосіб і набір для лікування або профілактики захворювань, які супроводжують тромбоутворення

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022910A1 (en) * 1993-03-29 1994-10-13 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
WO1995010295A1 (en) * 1993-10-15 1995-04-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides

Also Published As

Publication number Publication date
CN1238693A (zh) 1999-12-15
NO327740B1 (no) 2009-09-14
PL189116B1 (pl) 2005-06-30
DE69731763D1 (de) 2004-12-30
AU754936B2 (en) 2002-11-28
US20020032214A1 (en) 2002-03-14
SI0946185T1 (en) 2005-06-30
CZ298552B6 (cs) 2007-10-31
EP0946185B2 (en) 2010-05-05
DK0946185T3 (da) 2005-03-21
EA002475B1 (ru) 2002-06-27
DK0946185T4 (da) 2010-08-30
JP4498471B2 (ja) 2010-07-07
SK67399A3 (en) 2000-07-11
ATE283062T1 (de) 2004-12-15
BR9713141A (pt) 2000-02-08
DE69731763T3 (de) 2010-12-30
HUP9903496A3 (en) 2001-03-28
HK1023504A1 (en) 2000-09-15
AP9901517A0 (en) 1999-06-30
HUP9903496A2 (hu) 2000-10-28
UA63929C2 (uk) 2004-02-16
JP2001506603A (ja) 2001-05-22
NO992555D0 (no) 1999-05-27
IL129877A (en) 2004-08-31
AP1390A (en) 2005-04-15
ES2230624T5 (es) 2010-10-25
OA11049A (en) 2002-02-18
CA2272317C (en) 2001-01-30
NO992555L (no) 1999-05-27
CZ174299A3 (cs) 1999-09-15
PT946185E (pt) 2005-02-28
US6103705A (en) 2000-08-15
KR20000057265A (ko) 2000-09-15
CN1121224C (zh) 2003-09-17
BG64542B1 (bg) 2005-07-29
EP0946185B1 (en) 2004-11-24
BG103372A (en) 2000-01-31
WO1998023279A1 (en) 1998-06-04
ZA9710691B (en) 1998-06-12
ES2230624T3 (es) 2005-05-01
AU5454698A (en) 1998-06-22
SI0946185T2 (sl) 2010-08-31
EP0946185A1 (en) 1999-10-06
IL129877A0 (en) 2000-02-29
EA199900499A1 (ru) 2000-04-24
DE69731763T2 (de) 2005-06-30
EP0946185A4 (en) 2001-06-27
SK286024B6 (sk) 2008-01-07

Similar Documents

Publication Publication Date Title
KR100512671B1 (ko) 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물
Kumada et al. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals
Schipper et al. Antithrombin III deficiency in surgical intensive care patients
Schött et al. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran
Salta et al. Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots
Hennan et al. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury
JP3838680B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用
Rogers et al. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
KR20030069990A (ko) 항혈전 조성물
Tanaka et al. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan
Harenberg et al. Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor
Charef et al. Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally
MXPA99005008A (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
Ignasiak et al. Effects of intravenous enoxaparin and intravenous inogatran in an electrolytic injury model of venous thrombosis in the dog
HK1023504B (en) Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound
Kvasnička et al. Reduced thrombin generation and soluble P-selectin after intravenous enoxaparin during PCI
Nevarre et al. Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations
Malyszko et al. Conjugated estrogens shorten bleeding time in uraemia: a possible role of serotonin?
HK1161984B (en) Edoxaban dosage regime

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20110719

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120831

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120831